HC Wainwright Comments on Agenus' Q3 Earnings (NASDAQ:AGEN)

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Agenus Inc. to $2.63 per share, significantly up from a prior estimate of $0.25. The firm maintains a "Buy" rating with a price target of $25.00.
• Agenus recently reported a quarterly loss of ($1.00) EPS for Q2, which missed analyst expectations of ($0.78) EPS and generated revenues of only $25.70 million.
• Institutional investors hold 61.46% of Agenus' stock, with several firms, including Bank of Montreal and Gilead Sciences, making significant purchases in the recent quarter.

Agenus Inc. (NASDAQ:AGEN - Free Report) - Equities researchers at HC Wainwright increased their Q3 2025 earnings estimates for shares of Agenus in a report issued on Tuesday, August 12th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of $2.63 per share for the quarter, up from their previous forecast of $0.25. HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Agenus' current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus' Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at $0.03 EPS, FY2026 earnings at ($1.61) EPS, FY2027 earnings at ($3.35) EPS, FY2028 earnings at ($3.40) EPS and FY2029 earnings at ($0.71) EPS.

Other equities analysts also recently issued reports about the stock. B. Riley reiterated a "buy" rating on shares of Agenus in a report on Monday, April 21st. Zacks Research upgraded shares of Agenus to a "hold" rating in a report on Tuesday, August 12th. Wall Street Zen downgraded shares of Agenus from a "buy" rating to a "hold" rating in a research note on Sunday. Finally, Robert W. Baird increased their price objective on shares of Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research report on Wednesday, June 4th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $15.50.

Agenus Stock Performance

Shares of Agenus stock remained flat at $4.53 during trading hours on Thursday. 177,718 shares of the stock were exchanged, compared to its average volume of 829,391. The business's 50 day simple moving average is $5.34 and its 200 day simple moving average is $3.71. Agenus has a 12-month low of $1.38 and a 12-month high of $7.34. The stock has a market cap of $144.33 million, a PE ratio of -0.63 and a beta of 1.62.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The firm had revenue of $25.70 million for the quarter, compared to analysts' expectations of $49.71 million.

Institutional Investors Weigh In On Agenus

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC grew its position in shares of Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock valued at $90,000 after purchasing an additional 4,924 shares during the last quarter. Apollon Wealth Management LLC grew its position in shares of Agenus by 25.0% in the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 5,000 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Agenus in the second quarter valued at approximately $50,000. Jump Financial LLC acquired a new stake in shares of Agenus in the second quarter valued at approximately $55,000. Finally, Corton Capital Inc. acquired a new stake in shares of Agenus in the fourth quarter valued at approximately $36,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.